ALX Oncology to Present Results from Phase 1b/2 Trial of Evorpacept & Zanidatamab

ALX Oncology to Present Results from Phase 1b/2 Trial of Evorpacept & Zanidatamab

By, Admin 6 November 2024

ALX Oncology to present results from phase 1b/2 trial of evorpacept in combo with zanidatamab at SABCS 2024

Overview

ALX Oncology Holdings Inc., a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, announced that results from a phase 1b/2 combination trial evaluating ALX Oncology’s evorpacept in combination with Jazz Pharmaceuticals’ zanidatamab in HER2-positive and HER2-low metastatic breast cancer have been accepted for a poster spotlight presentation at the San Antonio Breast Cancer Symposium (SABCS), which will be held in San Antonio, Texas, from December 10-13, 2024.

Phase 1b/2 Clinical Trial

The phase 1b/2 clinical trial is a two-part, open-label, multicenter study (NCT05027139) that evaluated the potential of evorpacept in combination with zanidatamab as a novel treatment for patients with HER2-expressing breast cancer and other cancers.

Summarized Data

Data from this study will be summarized in the following poster spotlight presentation:

  • Title: Zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer: Results from a phase 1b/2 study 
  • Abstract Number: SESS-2007 
  • Presenter: Alberto J. Montero, M.D., MBA, Clinical Director, Breast Cancer Medical Oncology Programme, Diana Hyland Endowed Chair for Breast Cancer, and Professor of Medicine at University Hospitals Seidman Cancer Center, Case Western Reserve University 
  • Presentation Date and Time: Thursday, December 12, 7:00 a.m. – 8:30 a.m. CST 
  • Presentation ID: PS8-09 --Location: Henry B. Gonzalez Convention Center, San Antonio, Texas.

About the Company: ALX Oncology

  • ALX Oncology is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives. 
  • ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built.